February 13, 2024 03:47 PM EST
Pharma

In­cyte is 'op­ti­mistic' about skin dis­ease drug Opzelu­ra as pre­scrip­tions grow 77% in Q4

Katherine Lewin

News Reporter

In­cyte ex­pects its atopic der­mati­tis and vi­tili­go treat­ment Opzelu­ra to be a “key con­trib­u­tor” to growth in 2024 af­ter sales jumped 78% in the fourth …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times